ATS/Medtronic Expect Epicardial Angiogenesis Device Trials By 2003
This article was originally published in The Gray Sheet
Executive Summary
Human clinical trials of Advanced Tissue Sciences' Anginera tissue-engineered epicardial angiogenesis therapy could begin by late 2002 or early 2003 under an Oct. 3 strategic collaboration with Medtronic, ATS says.
You may also be interested in...
ATS Gives Smith & Nephew Second Skin; Wound Treatment Portfolio Elevated
Smith & Nephew's joint venture with Advanced Tissue Sciences to develop and market Dermagraft bio-engineered skin will be a major driver of S&N growth over the next five years, the British firm anticipates
ATS Gives Smith & Nephew Second Skin; Wound Treatment Portfolio Elevated
Smith & Nephew's joint venture with Advanced Tissue Sciences to develop and market Dermagraft bio-engineered skin will be a major driver of S&N growth over the next five years, the British firm anticipates
Bioheart Pursues OrCel Cardiac Regeneration; Ortec Chases Ulcer Claims
Bioheart, Inc.'s Myocell may provide Ortec entry into the cardiovascular regeneration market, under a deal covering the cell transplantation product in combination with Ortec's OrCel collagen sponge and vascular endothelial growth factor technologies